問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



Taichung Veterans General Hospital

Link to Hospital

  • 1,624

    Total Beds

  • 934

    Total Doctors

  • tcvghcrc@vghtc.gov.tw
  • Clinical Research Center
  • 04-23592525#4780
  • 407Taichung CityTaichung Xitun1650 Taiwan Boulevard Sect. 4, Taichung, Taiwan 407219, ROC

Recruiting Trial

576Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1334Cases

2006-09-01 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2011-05-23 - 2012-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2016-07-19 - 2018-06-25

Phase III

PIONEER 6 – Cardiovascular outcomes. A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    Oral Semaglutide

Participate Sites
4Sites

Terminated4Sites

2016-01-31 - 2017-02-10

Phase I

A dose-escalation and dose-expansion study of MEDI4736 (a monoclonal antibody that targets programmed cell death-1 ligand 1 (PD-L1)) will evaluate the safety, tolerability, PK, IM, and antitumor activity of MEDI4736 in adult patients with solid tumors. A dose exploration cohort will look at the safety profile of Q4W dosing of MEDI4736.

  • Condition/Disease

    NSCLC

  • Test Drug

    MEDI4736 & Tremelimumab

Participate Sites
8Sites

Not yet recruiting1Sites

Terminated7Sites

2015-04-01 - 2022-04-22

Phase III

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma (MM)

  • Test Drug

    Pomalidomide

Participate Sites
8Sites

Terminated7Sites

2020-12-31 - 2023-12-31

Phase II

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects with Sjögren’s Syndrome (SS)

  • Condition/Disease

    Sjögren’s Syndrome (SS)

  • Test Drug

    VIB4920

Participate Sites
5Sites

Recruiting5Sites

2018-09-01 - 2019-05-20

Phase III

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody) and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 <50%

  • Condition/Disease

    NSCLC

  • Test Drug

    REGN2810

Participate Sites
11Sites

Not yet recruiting10Sites

鍾飲文
Kaohsiung Municipal Gangshan Hospital

未分科

2018-03-08 - 2021-07-04

Phase III

A PHASE 3 MULTI-CENTER, LONG-TERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB, WITH OR WITHOUT TOPICAL MEDICATIONS, ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS

  • Condition/Disease

    Atopic dermatitis (AD)

  • Test Drug

    PF-04965842

Participate Sites
9Sites

Recruiting9Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2019-12-01 - 2022-12-20

Phase III

A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women in Asia Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause

  • Condition/Disease

    Severe Vasomotor Symptoms (Hot Flashes)

  • Test Drug

    Fezolinetant

Participate Sites
11Sites

Not yet recruiting8Sites

Recruiting1Sites

Terminated2Sites

2010-09-30 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 121 122 123 124 125 134
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB